Patent ID: 7351554

Claim:
A method for inducing a mucosal immunity with production of secretory IgA antibodies that neutralize or block a native E7 protein originating from cancerous cells, from cells infected by a human Papillomavirus (HPV) or from an immune system cell, said native E7 protein being locally immunosuppressive and/or angiogenic and said method comprising administering to a patient in need thereof, by the mucous membrane route, a vaccine pharmaceutical composition comprising: (i) an active compound selected from the group consisting of: said Immunosuppressive and/or angiogenic native E7 protein, the properties of which have been inactivated by at least 70% by a physical and/or a chemical treatment, by genetic recombination or also by adjuvant conditioning; an inactive fragment of said immunosuppressive and/or angiogenic native E7 protein; a DNA molecule encoding said immunosuppressive and/or angiogenic native E7 protein inactivated by at least 70% by mutation; and a DNA molecule encoding an inactive fragment of said immunosuppressive and/or angiogenic native E7 protein; and (ii) an adjuvant of mucosal immunity.